Prognostic value of coronary risk factors, exercise capacity and single photon emission computed tomography in liver transplantation candidates: A 5-year follow-up study

William E. Moody, PhD, MRCP, a Benjamin Holloway, FRCR, a Parthiban Arumugam, FRCP, MSc, b Sharon Gill, a Yasmin S. Wahid, a Chris M. Boivin, MPhil, a Louise E. Thomson, MBChB, FRACP, e Daniel S. Berman, MD, FACC, e Matthew J. Armstrong, PhD, MRCP, c,d James Ferguson, MD, FRCPE, c,d and Richard P. Steeds, MD, MA, FRCP a

a Department of Nuclear Medicine, Centre for Clinical Cardiovascular Science, Nuffield House, Queen Elizabeth Hospital Birmingham, University Hospital Birmingham NHS Foundation Trust, Edgbaston, UK
b Department of Nuclear Medicine, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK
c Department of Liver Medicine, Queen Elizabeth Hospital Birmingham, Edgbaston, UK
d Institute of Immunology and Immunotherapy, National Institute for Health Research (NIHR) Birmingham Liver Biomedical Research Centre (BRC), University of Birmingham, Birmingham, UK
e Departments of Imaging and Medicine, S. Mark Taper Foundation Imaging Center, Cedars-Sinai Medical Center, Los Angeles

Received Dec 9, 2019; accepted Mar 22, 2020
doi:10.1007/s12350-020-02126-z

Background. Although consensus-based guidelines support noninvasive stress testing prior to orthotopic liver transplantation (OLT), the optimal screening strategy for assessment of coronary artery disease in patients with end-stage liver disease (ESLD) is unclear. This study sought to determine the relative predictive value of coronary risk factors, functional capacity, and single photon emission computed tomography (SPECT) on major adverse cardiovascular events and all-cause mortality in liver transplantation candidates.

Methods. Prior to listing for transplantation, 404 consecutive ESLD patients were referred to a University hospital for cardiovascular (CV) risk stratification. All subjects met at least one of the following criteria: inability to perform > 4 METs by history (62%), insulin-treated diabetes mellitus (53%), serum creatinine > 1.72 mg/dL (8%), history of MI, PCI or CABG (5%), stable angina (3%), cerebrovascular disease (1%), peripheral vascular disease (1%). Subjects underwent Technetium-99m SPECT with multislice coronary artery calcium scoring (CACS) using exercise treadmill or standard adenosine stress in those unable to achieve 85% maximal heart rate (Siemens Symbia T16). Abnormal perfusion was defined as a summed stress score (SSS) ≥ 4.

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12350-020-02126-z) contains supplementary material, which is available to authorized users.
The authors of this article have provided a PowerPoint file, available for download at SpringerLink, which summarizes the contents of the paper and is free for re-use at meetings and presentations. Search for the article DOI on SpringerLink.com.
Funding WEM has received support as a BHF Clinical Research Fellow (FS/11/17/28700).

Reprint requests: William E. Moody, PhD, MRCP, Department of Nuclear Medicine, Centre for Clinical Cardiovascular Science, Nuffield House, Queen Elizabeth Hospital Birmingham, University Hospital Birmingham NHS Foundation Trust, EdgbastonB15 2TH; william.moody@nhs.net
1071-3581/$34.00
Copyright © 2020 The Author(s)
**Results.** Of the 404 patients, 158 (age 59 ± 9 years; male 68%) subsequently underwent transplantation and were included in the primary analysis. Of those, 50 (32%) died after a mean duration follow-up of 5.4 years (maximal 10.9 years). Most deaths (78%) were attributed to noncardiovascular causes (malignancy, sepsis, renal failure). Of the 32 subjects with abnormal perfusion (20%), nine (6%) had a high-risk perfusion abnormality defined as a total perfusion defect size (PDS) ≥ 15% and/or an ischemic PDS ≥ 10%. Kaplan–Meier survival curves demonstrated abnormal perfusion was associated with increased CV mortality (generalized Wilcoxon, $P = 0.014$) but not all-cause death. Subjects with both abnormal perfusion and an inability to exercise > 4 METs had the lowest survival from all-cause death ($P = 0.038$). Abnormal perfusion was a strong independent predictor of CV death (adjusted HR 4.2; 95% CI 1.4 to 12.3; $P = 0.019$) and MACE (adjusted HR 7.7; 95% CI 1.4 to 42.4; $P = 0.018$) in a multivariate Cox regression model that included age, sex, diabetes, smoking and the ability to exercise > 4 METs. There was no association between CACS and the extent of perfusion abnormality, nor with outcomes.

**Conclusions.** Most deaths following OLT are noncardiovascular. Nonetheless, abnormal perfusion is prevalent in this high-risk population and a stronger predictor of cardiovascular morbidity and mortality than functional status. A combined assessment of functional status and myocardial perfusion identifies those at highest risk of all-cause death. (Exercise Capacity and Single Photon Emission Computed Tomography in Liver Transplantation Candidates [ExSPECT]; ClinicalTrials.gov Identifier: NCT03864497). (J Nucl Cardiol 2020)

Key Words: SPECT • diagnostic and prognostic application • outcomes research • exercise testing • vasodilators

| Abbreviations          | Description                                      |
|------------------------|--------------------------------------------------|
| CAD                    | Coronary artery disease                          |
| CACS                   | Coronary artery calcium score                    |
| CV                     | Cardiovascular                                   |
| ESLD                   | End-stage liver disease                          |
| METs                   | Metabolic equivalents                            |
| OLT                    | Orthotopic liver transplantation                  |
| PDS                    | Perfusion defect size                            |
| SPECT                  | Single photon emission computed tomography       |
| SSS                    | Summed stress score                              |

**INTRODUCTION**

There is ongoing debate over the optimal screening method for coronary artery disease (CAD) in patients with end-stage liver disease (ESLD) being considered for transplantation. Although screening is widely practiced, no current strategy has yet been shown to improve outcomes in these subjects. In 2012, the American Heart Association and American College of Cardiology (AHA/ACC) published guidelines suggesting that regardless of functional status, the presence of ≥ 3 cardiovascular (CV) risk factors (age ≥ 60 years, diabetes mellitus, smoking, hypertension, dyslipidemia, left ventricular hypertrophy) should prompt screening of asymptomatic candidates under consideration for orthotopic liver transplantation (OLT).\(^1\) This was a consensus-based recommendation (Class IIb, Level of Evidence C), which reflects the limited quality of data evaluating the efficacy of perioperative risk stratification in this population. Those retrospective observational studies that are available report low sensitivity and specificity for both dobutamine stress echocardiography (DSE)\(^2-5\) and single photon emission computed tomography (SPECT) imaging in OLT candidates.\(^6,7\) This may in part, relate to the high resting myocardial blood flows associated with cirrhotic liver disease, which may lend itself poorly to pharmacological vasodilator stress.\(^5,8\) Nonetheless, in 2013 the American Association for the Study of Liver Diseases and American Society of Transplantation guidelines proposed DSE as “an effective screening test’’ in OLT candidates.\(^9,10\) In reality, most liver transplant centers tailor their choice of noninvasive stress imaging according to local expertise. This practice is supported by the latest data suggesting SPECT has equivalent efficacy compared with DSE in the identification of clinically significant CAD,\(^11\) and in keeping with an ACC Appropriate Use Criteria Task Force Report, which rated both modalities “appropriate’’ for ESLD subjects with poor functional capacity (< 4 METs).\(^12\)
The AHA/ACC recommendation to perform noninvasive screening in high-risk OLT candidates is supported by the finding that obstructive CAD on invasive angiography is more common in subjects referred with conventional risk factors. Despite this observation, traditional CV risk factors tend to perform poorly at predicting increased CV event rates in the ESLD population. In a retrospective analysis of 413 subjects undergoing liver transplant surgery, despite including all conventional CV factors in multivariate modeling, only a history of CAD or stroke were significant predictors of adverse cardiac outcomes at 30 days. In contrast, cardiopulmonary exercise testing (CPET) with measurement of estimated METs or maximum aerobic capacity, may offer more useful prognostic information in OLT candidates. Reduced aerobic capacity has been associated with worse outcomes following liver transplantation, although follow-up was limited to 90 and 100 days.

Controversy over whether SPECT imaging offers clinical utility in ESLD has been fueled by the conflicting reports on its accuracy to diagnose CAD in this setting. Moreover, there are no studies examining whether SPECT imaging provides any incremental prognostic value beyond functional testing in this high-risk cohort. We sought to determine, therefore, the relative importance of CV risk factors, functional capacity and SPECT perfusion as independent predictors of adverse outcome in OLT candidates.

**METHODS**

**Population**

ExSPECT (Exercise Capacity and Single Photon Emission Computed Tomography in Liver Transplantation Candidates) was an observational cohort study, including consecutive ESLD patients referred for cardiac evaluation between September 2007 and June 2018, prior to consideration for liver transplantation. In accordance with local guidelines, subjects were referred for noninvasive CV risk assessment if they fulfilled any of the following criteria: inability to perform > 4 METs by history, insulin-treated diabetes mellitus, serum creatinine > 1.72 mg/dl, history of MI, PCI or CABG, stable angina, cerebrovascular disease, or peripheral vascular disease. The conduct and reporting of this study was in line with the principles of the Declaration of Helsinki and guided by the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) Statement. The study was approved by the University Hospital Birmingham NHS Divisional Clinical Quality Group (CARMS-14536) and was registered with ClinicalTrials.gov (NCT03864497).

**Clinical Data**

The data that support the findings of this study are available from the corresponding author upon reasonable request. Demographic and anthropometric data were prospectively entered onto the patient’s electronic record. In addition, a standardized pre-scan clinical assessment was carried out including a detailed interview which elicited patient symptoms, CV risk factors, previous CV events, the cause for liver disease, the model for end-stage liver disease (MELD) score and medication history. Routine hematology and biochemistry indices at the time of the SPECT/CT imaging were also recorded. Diabetes mellitus (DM) was defined as a fasting glucose > 126 mg/dL, previous history of diabetes mellitus, or currently receiving hypoglycemic treatment. Hypertension was defined as an office blood pressure > 140/90 mmHg, or currently taking antihypertensive medication. Hypercholesterolemia was defined as a serum cholesterol of > 193 mg/dL, or currently taking lipid reduction therapy. History of CV disease included known coronary artery disease (myocardial infarction, previous percutaneous or surgical revascularization), heart failure, stroke, and peripheral vascular disease. Significant family history of CV disease was defined as a first degree relative with a history of myocardial infarction or ischemic stroke aged younger than 55 years in men and younger than 65 years in women.

**SPECT/CT**

Patients were asked to discontinue β-blockers, rate-limiting calcium channel blockers, and caffeine products 24 hours before testing, and nitrate compounds were discontinued more than 6 hours before testing. All participants underwent 2-day stress-rest Technetium-99m SPECT imaging (Symbia T16, Siemens, Erlangen, Germany). Those patients capable of exercise underwent treadmill stress. Standard adenosine stress was performed (140 µg/kg/min for 6 minutes) in those subjects unable to exercise or unable to achieve 85% of age-predicted maximal heart rate. Hemodynamic response to adenosine was assessed by comparing hemodynamics at rest and after 3 to 4 minutes of adenosine infusion, immediately prior to radiotracer administration. An inadequate response was defined as a decrease in systolic blood pressure of < 10 mmHg or heart rate increase < 10 beats/min with adenosine infusion. CT-based attenuation correction was performed in all patients during reconstruction of the SPECT data. Multislice coronary artery calcium scoring (CACS) was also performed as routine in subjects without a
history of myocardial infarction or coronary revascularization.

SPECT myocardial perfusion images were visually analyzed by two experienced observers (R.P.S. and B.H.) blinded to outcome variables (Hermes Medical Solutions, Quantitative Perfusion SPECT, Stockholm, Sweden). In addition to examination of raw images in cine mode, both nonattenuated and attenuated images were reviewed and a report was produced consistent with recommendations from the American Society of Nuclear Cardiology Imaging Guidelines for Nuclear Cardiology Procedures. Short-axis and vertical long-axis tomograms were divided into 17 segments for each study, and segmental tracer uptake was evaluated using a validated semi-quantitative 5-point scoring system (0, normal; 1, equivocal; 2, moderate; 3, severe reduction of radioisotope uptake; and 4, absence of detectable tracer uptake). The summed stress and rest scores were obtained by adding the scores of the 17 segments of the respective images. The sum of the differences between each of the 17 segments from these images was defined as the summed difference score, representing the amount of ischemia. These indices were converted to the percentage of total myocardium involved with stress, ischemic, or fixed defects by dividing the summed scores by 68 (the maximum potential score = 4 × 17), and multiplying by 100. The presence of abnormal perfusion was defined as a summed stress score (SSS) of 4 or greater. A stress-induced total perfusion defect size (PDS) > 15% or an ischemic PDS > 10% defined high risk for cardiac events. Cardiac volumes and left ventricular ejection fraction were calculated from the gated SPECT images (QGS 2012, Cedars-Sinai Medical Center, Los Angeles, CA, USA).

The CACS was calculated according to Agatston et al., by the same two independent observers in subjects without known coronary artery disease blinded to outcome data. Lesions were manually traced on CT images before semiautomated quantification derived vessel-specific scores were summed to yield the total CACS (SyngoVia, Leonardo, Siemens Medical Solutions, Forchheim, Germany). Minimal, mild, moderate, and severe coronary calcification were defined as Agatston scores of 0 to 10 U, 11 to 100 U, 101 to 400 U and > 400 U, respectively.

**Exercise Stress Testing**

Exercise treadmill testing (ETT) was carried out according to standard protocols (Bruce and modified Bruce) aiming to achieve > 85% of age-predicted maximal heart rate with a goal test duration of between 8 and 12 minutes. During exercise, data on symptoms, rhythm, heart rate, blood pressure (by indirect arm-cuff sphygmomanometry), and estimated workload in metabolic equivalents (METs) were recorded and entered prospectively into the patient electronic record. A positive test was defined as one showing 1mm of ST segment elevation or depression (of any morphology and in any lead except aVR) 80 msec after the end of the QRS complex any time after exercise was begun. A negative test was one without this degree of ST segment change and in which the patient achieved 85% of the maximum predicted heart rate for his age. All other tests were considered indeterminate. To improve the estimated accuracy of exercise capacity, patients were explicitly told not to lean on handrails during exercise. Estimated functional capacity in METs was estimated from the total time completed in the final stage; a MET is a measure of oxygen consumption defined as 1 kcal/kg/hour (equivalent to 3.5 ml of Oxygen/kg/min), which represents basal, rest metabolic needs. The Bruce protocol formula was used for estimating maximal oxygen uptake (VO2 max).

**Coronary Angiography**

Those patients with a high-risk perfusion abnormality on SPECT MPI were considered for invasive coronary angiography. The decision to proceed to angiography +/- invasive revascularization was made by the individual treating physician after each case was discussed in a dedicated multidisciplinary team meeting.

**End Points**

The primary outcome measure was cardiovascular death. Major adverse cardiovascular events (MACE) and all-cause mortality were examined separately as secondary outcomes. Major adverse cardiovascular events were defined as a composite endpoint of cardiac death, nonfatal myocardial infarction (MI), malignant arrhythmia, ischemic stroke, or hospitalization for congestive heart failure. Myocardial infarction was defined as a clinical (or pathologic) event caused by myocardial ischemia where there is evidence of myocardial injury or necrosis as defined by a rise and/or fall of cardiac biomarkers in the presence of typical symptoms or electrocardiographic changes, or imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. For the primary analysis, patients who did not undergo liver transplant surgery during the study period were identified and excluded from follow-up because of the strong mortality benefit associated with OLT in cirrhotic liver disease (see Data Supplement for outcome analysis including all consecutive subjects). Similarly, patients who had revascularization...
procedures within 90 days of an abnormal baseline SPECT imaging study were excluded to remove outcomes driven temporally by this result.35 Every patient in the NHS has a unique identifier which enables outcomes to be tracked using the Hospital Episodes Statistics (HES) Database, an administrative data warehouse containing admissions to all National Health Service hospitals in England.36 It contains detailed records relating to individual patient treatments, with data extraction facilitated using codes on procedural classifications (Office of Population Censuses and Surveys Classification of Interventions and Procedures, 4th revision (OPCS-4)) and medical classifications (World Health Organization International Classification of Disease, 10th revision (ICD-10)).37,38 With regard to outcome analysis, HES data alone have the limitation of only capturing deaths occurring in a hospital setting. To obtain the complete mortality list, the study cohort was also cross-referenced with mortality data from the Office for National Statistics (ONS), which collects information on all registered deaths in the UK.

An endpoint committee consisting of a cardiologist (W.E.M) and a hepatologist (J.F) adjudicated all outcomes by consensus. Outcomes were further verified by cross-referencing with individual hospital case notes held electronically. The endpoint committee was blinded to all clinical and imaging results.

Statistics
Statistical analyses were performed with SPSS version 25 (IBM, Armonk, New York, US). Data are expressed as mean ± SD, median (interquartile range), or frequency (%), unless otherwise stated. The normality of distribution for continuous variables was determined using normality plots and the Kolmogorov-Smirnov test. Baseline characteristics of the population were examined by SPECT results. The Mann-Whitney U test was used to compare continuous nonparametric data. The Kruskal-Wallis analysis of variance was used to identify significant differences in central tendencies of continuously scaled variables between groups. Contingency table analysis was performed using Chi-square or Fisher’s exact tests where appropriate.

Annualized mortality rates are expressed as the number of patients having cardiovascular or all-cause death as a proportion of the number of patients at risk divided by the number of patient-years follow-up. Kaplan-Meier analysis of outcomes was based on discrete SPECT and exercise capacity categories. The date of the imaging test was used as time zero. Two-sided generalized Wilcoxon tests were used to determine significance. Multivariate Cox proportional hazards models were used to identify the association between time-to-event and baseline clinical characteristics, estimated METs, and SPECT results. The change in the global Chi-square statistic was calculated to determine the incremental prognostic value of clinical, exercise and SPECT data; the Chi-square of the model was calculated from the log likelihood ratio. A P value <0.05 was considered statistically significant for all analyses.

RESULTS
Of the 404 patients with ESLD undergoing SPECT imaging between September 2007 and June 2018, 160 subjects subsequently underwent OLT. Reasons for patients not proceeding to OLT included compensated cirrhosis, extra-hepatic malignancy, hepatopulmonary syndrome, hepatorenal syndrome, severe obesity, malnutrition, active substance abuse, and psychosocial issues. Two patients without a prior diagnosis of coronary atheroma were excluded after undergoing early revascularization driven by the SPECT imaging demonstrating an ischemic PDS ≥ 10%. This resulted in 158 subjects available for inclusion in the present analysis (Figure 1). The demographics and outcomes for all consecutive patients (n = 404) are provided in the Data Supplement.

The baseline demographics and clinical characteristics of the study cohort are summarized in Table 1. Mean age was 57 years, 70% were male, 50% were diabetic, and 11% were hypertensive. Almost all patients were asymptomatic (97%). Table 2 summarizes the results of the functional assessment and imaging characteristics for all included subjects. The median time between SPECT imaging and liver transplant was 4 months (IQR 2.1 to 9.0)

SPECT/CT
Abnormal perfusion was identified in 32 of the 158 patients (20%). Of those, 9 subjects (6%) had a high-risk perfusion abnormality, which was associated with a lower left ventricular ejection fraction on gated analysis (Table 3). There was no difference in the mean number of cardiac risk factors between subjects with a normal SPECT result and those with abnormal perfusion or a high-risk perfusion abnormality. There was, however, a graded association between the size of perfusion defect and the proportion of subjects with hypercholesterolemia. Subjects with abnormal perfusion on SPECT showed a trend toward higher CAC scores but
this result did not reach significance \((P = 0.087, \text{Table 3}).\)

The relationship between CACS and SPECT results is displayed in Figure 2. Most patients had zero, minimal or mild CAC (71%). The majority of those with minimal CACS (90%) had normal perfusion, although 4 subjects (10%) with minimal CACS did demonstrate a high-risk SPECT profile based on a stress-induced total PDS \(\geq 15\%\). Those subjects with at least moderate CAC (29%) were more likely to have diabetes (Chi-square = 4.2, \(P = 0.04\)) although there was no association between increasing CACS and any other traditional risk factor.

**Exercise**

There was no significant association between the ability to perform treadmill exercise and the likelihood of having a perfusion defect or the CACS severity. In the 77 patients (49%) who underwent exercise stress, there was no association between the number of METS achieved and the likelihood of an abnormal perfusion result (Table 3). There was, however, a weak correlation between increasing CACS and reduced METS \((\rho = -0.45, P = 0.046)).\

**Coronary Angiography**

Of the 9 subjects with a high-risk perfusion abnormality by SPECT (total PDS \(\geq 15\%\)), 6 patients had an ischemic PDS \(\geq 10\%). Of those, 3 subjects proceeded to invasive coronary angiography. Subsequently, 2 patients were diagnosed with nonobstructive coronary disease and 1 patient with obstructive coronary disease.

**Outcomes**

There were a total of 50 deaths (32%) after a mean duration of 5.4 years (maximal follow-up 10.9 years), and most (78%) were attributed to noncardiovascular causes (Table 4). Kaplan–Meier survival curves demonstrate abnormal perfusion was associated with increased CV mortality (generalized Wilcoxon, \(P = 0.014\)) but not all-cause death (Figure 3). Although there was a trend toward increased CV mortality in those patients with impaired functional status (Figure 4), this result did not reach statistical significance (generalized Wilcoxon, \(P = 0.24\)). Similarly, on Kaplan–Meier survival analysis, for patients that underwent adenosine stress (i.e., those patients unable to perform treadmill exercise) there was a trend toward increased CV and all-cause mortality but
Table 1. Baseline demographics and clinical characteristics for study cohort

| Variable                                      | N = 158 |
|-----------------------------------------------|---------|
| Age (years)                                   | 56.6 ± 8.9 |
| Male sex                                      | 110 (70%) |
| Ethnicity                                     |         |
| White                                         | 135 (85%) |
| Asian                                         | 20 (13%)  |
| Afro-Caribbean                                | 1 (1%)   |
| Other                                         | 2 (1%)   |
| Body mass index (kg/m²)                       | 29.9 ± 6.1 |
| Etiology of end-stage liver disease           |         |
| Alcohol                                       | 36 (23%) |
| Hepatitis B                                   | 1 (1%)   |
| Hepatitis C                                   | 21 (17%) |
| Nonalcoholic steatohepatitis                  | 29 (19%) |
| Primary biliary cirrhosis                     | 10 (6%)  |
| Cryptogenic                                   | 2 (1%)   |
| Autoimmune                                    | 2 (1%)   |
| Alpha-1-antitrypsin deficiency                | 2 (1%)   |
| Other                                         | 35 (29%) |
| MELD score                                    | 16 ± 6   |
| Cardiac risk factors                          |         |
| Diabetesa                                      | 79 (50%) |
| Hypertension                                  | 17 (11%) |
| Hypercholesterolemia                          | 42 (27%) |
| Current smoker                                | 28 (18%) |
| Family history of CAD                         | 2 (1%)   |
| Number of cardiac risk factors                | 1.7 ± 1.0 |
| Symptomatic chest pain                        | 2 (1%)   |
| Typical angina/atypical or noncardiac         | 1 (1%)/1 (1%) |
| History of revascularization (PCI or CABG)    | 5 (3%)   |
| History of myocardial infarction              | 5 (3%)   |
| Medications                                   |         |
| Aspirin                                       | 17 (11%) |
| Beta-blocker                                  | 77 (49%) |
| ACE inhibitor/angiotensin receptor blocker    | 15 (9%)  |
| Calcium channel blocker                       | 2 (1%)   |
| Loop diuretic                                 | 40 (25%) |
| Mineralocorticoid receptor antagonist         | 50 (32%) |
| Statin                                        | 35 (22%) |
| Insulin                                       | 77 (49%) |
| Hemoglobin (g/L)                              | 117 (105–129) |
| Total cholesterol (mg/dL)                     | 157 ± 54 |
| INR                                           | 1.36 ± 0.33 |
| Creatinine (mg/dL)                            | 0.90 (0.75–1.15) |

Data are number (%), mean ± SD or median (IQR)

*aOn Insulin or oral hypoglycemic therapy

ACE, angiotensin converting enzyme; CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; IQR, interquartile range; PCI, percutaneous coronary intervention
this association did not reach significance ($P = 0.398$ and $P = 0.791$, respectively, Figure 4). There was, however, incremental predictive value when integrating the results of functional testing and SPECT imaging (Figures 5, 6, 7); subjects with both abnormal perfusion and an inability to exercise ($\leq 4$ METs had elevated cardiovascular and all-cause mortality (generalized Wilcoxon, $P = 0.004$ and $P = 0.038$, respectively).

Abnormal perfusion was an independent predictor of CV death albeit with wide confidence intervals (Table 5; adjusted HR 4.2; 95% CI 1.4 to 13.7; $P = 0.019$) and MACE (adjusted HR 7.7; 95% CI 1.4 to 42.4; $P = 0.018$) in a multivariate Cox regression model that included age, sex, diabetes, smoking and the ability to exercise ($\leq 4$ METs. There was no significant association between CACS and adverse outcomes. One patient with a minimal CACS suffered a sudden cardiac death.

In subjects with abnormal perfusion by SPECT ($\geq 4$), the annualized cardiovascular death rate was 2.6% versus 1.0% in those with normal perfusion ($P < 0.001$). Subjects with abnormal perfusion and who were unable to exercise ($\geq 4$ METs experienced the highest annualized cardiovascular and all-cause mortality rates (3.9% and 28.3%, respectively; Figure 6). Only 7 out of the 126 subjects (5.5%) with normal SPECT perfusion suffered a CV death after a mean follow-up of 5.4 years; four of these subjects underwent adenosine stress and 3 had exercise stress testing.

Figure 7 depicts the incremental value of stress SPECT results over clinical data to predict cardiovascular death by global Chi-square analysis. There was a significant improvement in risk prediction with the addition of abnormal perfusion on SPECT to clinical information and exercise capacity (Chi-square change = 4.7, $P = 0.04$).

**DISCUSSION**

In the longest follow-up survival study of OLT candidates undergoing noninvasive stress imaging to date, we have shown that abnormal perfusion is common in this high-risk population (20%) and is a stronger predictor of cardiovascular morbidity and mortality than functional status. The addition of abnormal perfusion to coronary risk factors and exercise capacity provides incremental prognostic utility for the prediction of CV death. Nonetheless, most subjects die from non-CV causes and a combined assessment of functional status and myocardial perfusion identifies those at highest risk of all-cause mortality. Cardiorespiratory fitness (as defined by estimated METs) and abnormal perfusion (as determined by SPECT); therefore, both appear to be important predictors of adverse long-term outcomes post-liver transplantation.

There are limited quality studies guiding clinicians on risk stratification in the perioperative period (at the time of transplantation and in the postoperative period out to 6 months) but even less data addressing risk beyond 6 months, when the patient is thought to be more commonly on a reduced immunosuppression regime. To date, almost all follow-up studies involving noninvasive stress testing for risk stratification prior to OLT have

### Table 2. Functional assessment and imaging characteristics for study cohort

| Variable | N = 158 |
|----------|---------|
| Exercise treadmill stress | 77 (49%) |
| METs achieved<sup>a</sup> | 6.3 ± 2.4 |
| Peak VO<sub>2</sub> achieved (ml/kg/min)<sup>a</sup> | 22.2 ± 8.4 |
| Positive/indeterminate/negative<sup>a</sup> | 2 (3%) / 13 (17%) / 61 (80%) |
| LV ejection fraction, % | 60.9 ± 7.9 |
| Abnormal SPECT<sup>b</sup> | 32 (20%) |
| Summed stress score ≥ 9 | 9 (6%) |
| Total PDS ≥ 15% | 9 (6%) |
| Ischemic PDS ≥ 10% | 6 (4%) |
| CACS, Agatston units (IQR)<sup>c</sup> | 11 (0–119) |

Data are number (%), mean ± SD or median (IQR)

<sup>a</sup>In the 77 patients that were capable of exercise treadmill exercise stress

<sup>b</sup>Defined as summed stress score of 4 or more

<sup>c</sup>In the 84 patients for whom data were available

CACS, coronary artery calcium score; LV, left ventricular; METs, metabolic equivalents; PDS, perfusion defect size; SPECT, single photon emission computed tomography; VO<sub>2</sub>, oxygen uptake
Table 3. Baseline demographics, clinical characteristics, and stress test differences by SPECT results (N = 158)

| Variable                      | Normal perfusion (N = 126) | Abnormal perfusion (N = 32) | P value<sup>a</sup> | Total PDS <15% (N = 23) | Total PDS ≥15% (N = 9) | P value<sup>b</sup> |
|-------------------------------|-----------------------------|-----------------------------|---------------------|-------------------------|-------------------------|---------------------|
| Age                           | 56.5 ± 7.9                  | 56.9 ± 8.3                  | 0.78                | 57.5 ± 9.1              | 55.0 ± 6.0              | 0.16                |
| Male                          | 84 (67%)                    | 26 (81%)                    | 0.10                | 19 (83%)                | 7 (78%)                 | 0.43                |
| Cardiac risk factors          |                             |                             |                     |                         |                         |                     |
| Diabetes                      | 63 (50%)                    | 16 (50%)                    | 0.51                | 13 (57%)                | 3 (33%)                 | 0.19                |
| Hypertension                  | 15 (12%)                    | 2 (6%)                      | 0.33                | 2 (9%)                  | 0 (0%)                  | 0.46                |
| Hypercholesterolemia          | 27 (21%)                    | 15 (47%)                    | 0.26                | 10 (44%)                | 5 (56%)                 | 0.02                |
| Smoking history               | 27 (21%)                    | 7 (22%)                     | 0.75                | 5 (22%)                 | 2 (22%)                 | 0.92                |
| Able to perform exercise stress |                             |                             |                     |                         |                         |                     |
| METs<sup>c</sup>              | 6.6 ± 2.5                   | 5.5 ± 1.6                   | 0.15                | 5.1 ± 1.1               | 7.4 ± 2.8               | 0.12                |
| LV ejection fraction, %       | 62.2 ± 9.7                  | 55.5 ± 8.2                  | 0.01                | 56.6 ± 7.1              | 54.4 ± 9.8              | 0.02                |
| CACS, Agatston units (IQR)<sup>d</sup> | 7 (0-113) | 38 (11-260) | 0.09 | 48 (11-419) | 11 (1-36) | 0.52 |

Data are N (%), mean ± SD or median (interquartile range)
CACS, coronary artery calcium score; METs, metabolic equivalents; PDS, perfusion defect size; LV, left ventricular
<sup>a</sup>Normal perfusion versus abnormal perfusion
<sup>b</sup>Normal SPECT versus total PDS <15% versus total PDS ≥15%. The Kruskal-Wallis analysis of variance was used to identify significant differences in central tendencies of continuously scaled variables between groups. Contingency table analysis was performed using Chi-square or Fisher’s exact tests where appropriate
<sup>c</sup>In the 77 subjects capable of treadmill exercise
<sup>d</sup>Coronary artery calcium scoring was performed in 84 patients without a known history of myocardial infarction or revascularization and with resting heart rates < 80 bpm. The numbers of patients per subgroup were as follows: normal perfusion (n = 60), abnormal perfusion (n = 24); total PDS <15% (n = 20); total PDS ≥15% (n = 4)
focused on perioperative outcomes. One of the major advantages of the current study is its ability to inform clinicians on intermediate and long-term outcomes. This is particularly relevant because liver grafts have become an increasingly scarce commodity; clinicians, therefore, have an important duty to ensure that graft survival is not limited by premature CV death. Based on the current study, the incorporation of combined functional and perfusion data into pre-operative risk stratification should help facilitate appropriate resource allocation, which in turn may lead to better overall long-term outcomes for patients with ESLD.

In our institution, SPECT imaging is reserved for high-risk candidates; only 49% of subjects were capable of treadmill exercise stress and 50% were diabetic. Using this pre-op risk stratification strategy, the 5-year survival for this specific cohort was 68%. Taking into account the high-risk baseline profile of this selected population, this figure compares favorably with the unadjusted 5-year survival rate for adult liver transplant recipients (72%) reported by the U.S. Organ Procurement and Transplantation Network. In keeping with a study from Zoghbi et al., which included 82 patients undergoing SPECT, most of our patients suffered a non-CV death, although the frequency of abnormal perfusion was notably higher in our cohort (20% vs. 9%). This finding might be explained by the higher proportion of males (70% vs. 63%) and active smokers (18% vs. 12%), as well as a higher prevalence of diabetes mellitus (50% vs. 16%).

A small proportion of subjects with normal SPECT perfusion (5.5%) suffered a CV death after an extended period of follow-up (mean 5.4 years), although only one occurred within the first 6 months. It is well recognized that the highest risk period is often at the time of donor liver reperfusion when unstable arrhythmia can be induced. It is conceivable that perioperative CV events might occur in the absence of ischemia in patients with lactatemia, acidosis, hypoxia, hypotension, or electrolyte disturbances, which may predispose to acquired electrocardiogram abnormalities such as a prolonged QT interval. Despite prior concerns about the sensitivity of vasodilator stress SPECT testing in patients with cirrhotic liver disease and high resting myocardial blood flows, the current data suggest it has the ability to detect prognostically important CV disease in the short- and intermediate-term.

There was incremental prognostic utility from adding SPECT perfusion data to traditional coronary risk factors and these findings contrast with a recent report suggesting a simple assessment of traditional CV risk factors was equivalent to SPECT imaging in its diagnostic ability to predict significant coronary artery disease. In our cohort, smoking was the only conventional risk factor independently associated with reduced CV survival. Roughly one half of this cohort constituted asymptomatic diabetic patients but in contrast to abnormal perfusion, the presence of diabetes was not an independent predictor of premature CV death. This finding needs to be taken into consideration with the results of the DIAD study, which showed that screening asymptomatic diabetic with SPECT MPI did not

**Figure 2.** Relation between CACS severity and stress SPECT results (n = 84). The percentage of subjects with a normal SPECT result was highest in those with minimal CACS (P < 0.001). A 4 × 2 contingency analysis was performed using a two-tailed Fisher’s exact test to determine significance.

**Table 4.** Follow-up (N = 158)

| Mortality, all-cause | 50 (32%) |
|----------------------|----------|
| Cardiovascular       | 11       |
| Infection            | 10       |
| Bleeding             | 2        |
| Malignancy           | 17       |
| Multi-organ/renal failure | 3   |
| Recurrent liver disease | 6     |
| Other                | 1        |

| Major adverse cardiac events | 19 (12%) |
|-----------------------------|----------|
| Cardiovascular death        | 11       |
| Fatal myocardial infarction | 4        |
| Sudden cardiac death        | 4        |
| Ischemic stroke             | 3        |
| Nonfatal myocardial infarction | 1     |
| Revascularizationa           | 2        |
| Aborted sudden cardiac death | 2       |
| Nonfatal ischemic stroke    | 2        |
| Congestive heart failure    | 1        |

Values are N (%) or N

*aLate revascularization > 90 days after the SPECT/CT imaging
confer an improvement in CV outcomes over a similar follow-up period (4.8 years).

In the general population, there is a well-recognized inverse association between functional status and mortality, independent of age, sex, and ethnicity. In a recent cohort study including 122,007 patients undergoing treadmill testing, the increase in all-cause mortality associated with reduced cardiorespiratory fitness (as defined by peak estimated metabolic equivalents (METs)) was comparable to or greater than for traditional CV risk factors. The current data support that functional status has an equally important prognostic role in patients with ESLD.

In a retrospective study of OLT candidates referred for screening SPECT at a single institution, only 8% of studies were deemed abnormal. A total of 26 patients with positive SPECT and angiographic evidence of CAD were denied transplantation; however, CAD was the only factor for denial in only 7 patients. The analysis demonstrated that the screening
Stress MPI results were not associated with liver transplantation eligibility and suggested that because of the large number of competing factors considered prior to transplantation and the low prevalence of abnormal stress MPI results, screening for CAD should be reserved for patients deemed otherwise acceptable for transplantation. The higher prevalence of abnormal SPECT perfusion in the current study suggests that reserving screening to asymptomatic patients who are at elevated baseline risk (unable to perform > 4 METs, presence of diabetes, smoking, renal dysfunction) is an acceptable strategy and might increase the influence of stress MPI findings.

Identifying advanced CAD in the form of detectable CAC may offer an alternative strategy to recognize vulnerable patients. Severe coronary artery calcification (CACS > 400 U) is predictive for revascularization, and of 30-day post-LT cardiovascular complications, although data supporting an increased risk in OLT patients after the initial postoperative period.

**Figure 5.** Kaplan–Meier curve for unadjusted cumulative survival from (A) cardiovascular death and (B) all-cause death according to integrated results of SPECT and exercise capacity. Two-sided generalized Wilcoxon tests were used to determine significance.

**Figure 6.** Annualized event rates for (A) cardiovascular death and (B) all-cause death according to integrated results of SPECT and exercise capacity. (A) For each subgroup (number of CV deaths/number of patients): METs ≥ 4, normal perfusion (1/59); METs <4, normal perfusion (4/67); METs ≥ 4, abnormal perfusion (2/15); METS <4, abnormal perfusion (4/17). (B) For each subgroup (number of all-cause deaths/number of patients): METs ≥ 4, normal perfusion (15/60); METs <4, normal perfusion (26/66); METs ≥ 4, abnormal perfusion (2/15); METS <4, abnormal perfusion (7/17).
are lacking. Of concern, the current study demonstrates that a minimal CACS in ESLD patients does not exclude the possibility of finding abnormal perfusion on SPECT. Furthermore, we found no association between CACS and outcomes, although this study was not designed to address this issue and was likely underpowered. The presence of coronary atheroma per se is unlikely to be the sole factor for excluding a patient from proceeding to OLT. Increased CACS does not form an indication for revascularization at any level and at present, a decision to deny a patient transplantation driven by increased CAC seems incorrect.

Although 10% of patients with minimal coronary calcification had an abnormal SPECT result, only one such patient suffered a major adverse cardiovascular event (a sudden cardiac death) and there were no adverse events in any patient with a CACS of zero after a mean follow-up of 5 years. These findings support the pragmatic approach recently proposed in this journal\textsuperscript{51,52} where coronary computed tomography angiography ± CACS can be used to exclude coronary disease with the added advantage of having a long warranty.

There are limitations to our study. These data are from consecutive patients recruited from a single center. The majority of patients were white males, which limits the generalizability of the results. Given that roughly half the cohort had diabetes, statin usage on study entry was relatively low (22%) and although baseline medications were recorded, we did not capture information on changes in medical therapy over the study period, which is a factor that may have influenced outcomes. A recent observational report suggested that so long as patients were appropriately revascularized, the severity or extent of CAD did not influence post-transplant survival, although follow-up was limited to only 90 days.\textsuperscript{53} We are unable to provide information on the influence of revascularization on OLT candidates because of the low numbers of subjects who underwent invasive coronary angiography. Our practice likely reflects the conclusions drawn from general population studies; randomized controlled trials have shown no benefit in prophylactic revascularization compared with medical therapy in stable patients undergoing surgery (even major vascular surgery) despite the presence of ischemia.\textsuperscript{54,55}

**CONCLUSION**

These data suggest that MPI SPECT provides incremental and independent prognostic value in OLT candidates. Based on the presence of risk factors, it appears reasonable to continue to risk stratify asymptomatic candidates with a noninvasive assessment that combines exercise testing and MPI SPECT imaging. More prospective evidence is required, however, ideally from randomized clinical trials, to guide the indications, timing, and outcomes of revascularization therapy in patients with ESLD.

### Table 5. Multivariate predictors of 5-year cardiovascular mortality

| Variable                  | Cardiovascular death | HR (95% CI) | P value |
|---------------------------|----------------------|-------------|---------|
| Age                       | 0.95 (0.88-1.04)     | 0.272       |
| Gender (female)           | 2.07 (0.56-7.64)     | 0.276       |
| Diabetes                  | 1.39 (0.87-7.59)     | 0.088       |
| Current smoker            | 5.23 (1.07-25.46)    | 0.041       |
| METs < 4                  | 2.73 (0.60-12.54)    | 0.196       |
| Abnormal perfusion\textsuperscript{a} | 4.18 (1.43-12.27) | 0.019       |

All variables listed were simultaneously entered into a multivariate Cox regression model

METs, metabolic equivalents

\textsuperscript{a}Defined as summed stress score ≥4

![Figure 7. Incremental predictive value of exercise capacity and stress SPECT results over clinical information to predict cardiovascular death. The clinical data entered into the global Chi-square analysis model included age, sex, diabetes, smoking history. Abnormality on SPECT (defined as SSS ≥ 4) and exercise capacity (METs < 4) were entered as binary variables.](image-url)
NEW KNOWLEDGE GAINED

Abnormal perfusion as defined by MPI SPECT, is prevalent in the liver transplant population and an independent predictor of cardiovascular death. MPI SPECT provides complementary prognostic value to functional testing—a combined assessment of cardiorespiratory fitness and myocardial perfusion identifies those subjects at highest risk of cardiovascular and all-cause death.

Acknowledgments

The co-authors are grateful to Ms Bridget Gunson, Manager of the National Institute for Health Research (NIHR) Birmingham Liver Biomedical Research Centre (BRC), University of Birmingham, for helping facilitate the extraction of outcomes data.

Disclosure

There are no relevant disclosures for any author.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, Carithers RL, Ragosta M, Bolton K, Auerbach AD, Eagle KA. Cardiac disease evaluation and management among kidney and liver transplantation candidates: A scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2012;60:434-80.
2. Snipelisky D, Levy M, Shapiro B. Utility of dobutamine stress echocardiography as part of the pre-liver transplant evaluation: An evaluation of its efficacy. Clin Cardiol 2014;37:468-72.
3. Harinstein ME, Flaherty JD, Ansari AH, Robin J, Davidson CJ, Rossi JS, Flamm SL, Blei AT, Bonow RO, Abecassis M, Gheorghide M. Predictive value of dobutamine stress echocardiography for coronary artery disease detection in liver transplant candidates. Am J Transpl 2008;8:1523-8.
4. Williams K, Lewis JF, Davis G, Geiser EA. Dobutamine stress echocardiography in patients undergoing liver transplantation evaluation. Transplantation 2000;69:2354-6.
5. Umphrey LG, Hurst RT, Eleid MF, Lee KS, Reuss CS, Hentz JG, Vargas HE, Appleton CP. Preoperative dobutamine stress echocardiographic findings and subsequent short-term adverse cardiac events after orthotopic liver transplantation. Liver Transpl 2008;14:886-92.
6. Davidson CJ, Gheorghide M, Flaherty JD, Elliot MD, Reddy SP, Wang NC, Sundaram SA, Flamm SL, Blei AT, Abecassis MI, Bonow RO. Predictive value of stress myocardial perfusion imaging in liver transplant candidates. Am J Cardiol 2002;89:359-60.
7. Bhutani S, Tobis J, Gevorgyan R, Sinha A, Suh W, Honda HM, Vorobiof G, Packard RR, Steadman R, Wray C, Busuttil R, Tseng CH. Accuracy of stress myocardial perfusion imaging to diagnose coronary artery disease in end stage liver disease patients. Am J Cardiol 2013;111:1057-61.
8. Abele JT, Rauhenheimer M, Bain VG, Wandzik G, AlHalaimi N, Coulden R, deKemp RA, Klein R, Williams RG, Warshawski RS, Lalonde LD. Quantitative blood flow evaluation of vasodilation-stress compared with dobutamine-stress in patients with end-stage liver disease using (82)Rb PET/CT. J Nucl Cardiol 2018;1:1.
9. Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014;59:1144-65.
10. VanWagner LB, Harinstein ME, Runo JR, Darling C, Serper M, Hall S, Kobashigawa JA, Hammel LL. Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: An evaluation of the evidence and consensus recommendations. Am J Transp 2018;18:30-42.
11. Snipelisky D, Ray J, Vallabhajosyula S, Matcha G, Squier S, Lewis J, Holliday R, Aggarwal N, Askew JW 3rd, Shapiro B, Anavekar N. Usefulness for predicting cardiac events after orthotropic liver transplantation of myocardial perfusion imaging and dobutamine stress echocardiography preoperatively. Am J Cardiol 2017;119:1008-11.
12. Wolk MJ, Bailey SR, Doherty JU, Douglas PS, Hendel RC, Kramer CM, Min JK, Patel MR, Rosenbaum L, Shaw LJ, Stainback RF, Allen JM, American College of Cardiology Foundation Appropriate Use Criteria Task F. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol 2013;60(3):380-406.
13. Tiukinhoy-Laing SD, Rossi JS, Bayram M, De Luca L, Gafoor S, Blei A, Flamm S, Davidson CJ, Gheorghide M. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol 2006;98:178-81.
14. Safadi A, Homsi M, Maskoun W, Lane KA, Singh I, Sawada SG, Mahenthiran J. Perioperative risk predictors of cardiac outcomes in patients undergoing liver transplantation surgery. Circulation 2009;120:1189-94.
15. Guckelberger O, Thelen A, Benckert C, Schoebel C, Reuter S, Klupp J, Jonas S, Neuhaus P. Diabetes mellitus is no independent risk factor for perioperative mortality following hepatic resection. Exp Clin Endocrinol Diabetes 2006;114:257-61.

16. Guckelberger O, Mutzeke F, Glanemann M, Neumann UP, Jonas S, Neuhaus R, Neuhaus P, Langrehr JM. Validation of cardiovascular risk scores in a liver transplant population. Liver Transpl 2006;12:394-401.

17. Appleton CP, Hurst RT. Reducing coronary artery disease events in liver transplant patients: Moving toward identifying the vulnerable patient. Liver Transpl 2008;14:1691-3.

18. Hogan BJ, Gonsalkorala E, Heneghan MA. Evaluation of coronary artery disease in potential liver transplant recipients. Liver Transpl 2017;23:386-95.

19. Prentis JM, Manas DM, Trenell MI, Hudson M, Jones DJ, Snowden CP. Submaximal cardiopulmonary exercise testing predicts 90-day survival after liver transplantation. Liver Transpl 2012;18:152-9.

20. Epstein SK, Freeman RB, Khayat A, Unterborn JN, Pratt DS, Kaplan MM. Aerobic capacity is associated with 100-day outcome after hepatic transplantation. Liver Transpl 2004;10:418-24.

21. Baker S, Chambers C, McQuillan P, Janicki P, Kadry Z, Bowen D, Bezinover D. Myocardial perfusion imaging is an effective screening test for coronary artery disease in liver transplant candidates. Clin Transplant 2015;29:319-26.

22. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandebroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Epidemiology 2007;18:800-4.

23. Karamitsos TD, Ntusi NA, Francis JM, Holloway CJ, Myerson SG, Neubauer S. Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2010;12:66.

24. Holly TA, Abbott BG, Al-Mallah M, Calnon DA, Cohen MC, DiFilippo FP, Ficaro EP, Freeman MR, Hendel RC, Jain D, Leonard SM, Nichols KJ, Polk DM, Soman P. Single photon-emission computed tomography. J Nucl Cardiol 2010;17:941-73.

25. Berman DS, Kiat H, Friedman JD, Wang FP, van Train K, Matzer L, Maddahi J, Germaino G. Separate acquisition rest thallium-201/ stress technetium-99m sestamibi dual-isotope myocardial perfusion single-photon emission computed tomography: A clinical validation study. J Am Coll Cardiol 1993;22:1455-64.

26. Hachamovich R, Berman DS, Shaw LJ, Kiat H, Cohen I, Cabico JA, Friedman J, Diamond GA. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: Differential stratification for risk of cardiac death and myocardial infarction. Circulation 1998;97:535-43.

27. Chang SM, Nabi F, Xu J, Peterson LE, Achari A, Pratt CM, Mahmarian JJ. The coronary artery calcium score and stress myocardial perfusion imaging provide independent and complementary prediction of cardiac risk. J Am Coll Cardiol 2009;54:1872-82.

28. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827-32.

29. Rumberger JA, Brundage BH, Rader DJ, Kondos G. Electron beam computed tomographic coronary calcium scanning: A review and guidelines for use in asymptomatic persons. Mayo Clin Proc 1999;74:243-52.

30. Bruce RA. Exercise testing of patients with coronary heart disease. Principles and normal standards for evaluation. Ann Clin Res 1971;3:323-32.

31. Gibbons RJ, Balady GJ, Bricker JT, Chairmain BR, Fletcher GF, Froelicher VF, Mark DB, McCallister BD, Moos AN, O’Reilly MG, Winters WL Jr, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hirtzka LF, Jacobs AK, Russell RO, Smith SC Jr. American College of Cardiology/American Heart Association Task Force on Practice G. ACC/AHA 2002 guideline update for exercise testing: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002;2002(106):1883-92.

32. Jette M, Sidney K, Blumberg M. Metabolic equivalents (METs) in exercise testing, exercise prescription, and evaluation of functional capacity. Clin Cardiol 1990;13:555-65.

33. Bruce RA, Kusumi F, Hosmer D. Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. Am Heart J 1973;85:546-62.

34. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.

35. Shah R, Gleadle JM, Selvanayagam JB. Predicting cardiac prognosis in asymptomatic chronic kidney disease patients. JACC Cardiovasc Imaging 2018;11:286-7.

36. National Health Service HSCIC. Hospital Episodes Statistics Online Database 2019. www.hesonline.nhs.uk. Accessed 1 Aug 2019.

37. National Health Service. OPICS-4 Classification e NHS connecting for health 2019. www.connectingforhealth.nhs.uk. Accessed 1 Aug 2019.

38. World Health Organisation. International classification of diseases (ICD) 2019. www.who.int/classifications/icd/en. Accessed 1 Aug 2019.

39. Kong YG, Kang JW, Kim YK, Seo H, Lim TH, Hwang S, Hwang GS, Lee SG. Preoperative coronary calcium score is predictive of early postoperative cardiovascular complications in liver transplant recipients. Br J Anaesth 2015;114:437-43.

40. Organ Procurement and Transplantation Network. Health Resources and Services Administration. US Department of Health. 2019. https://optn.transplant.hrsa.gov. Accessed 1 Aug 2019.

41. Zoghbi GJ, Patel AD, Ershadi RE, Heo J, Bynon JS, Iskandrian AE. Usefulness of preoperative stress perfusion imaging in predicting prognosis after liver transplantation. Am J Cardiol 2003;92:1066-71.

42. Appleton CP, Hurst RT, Lee KS, Reuss C, Hentz JG. Long-term cardiovascular risk in the orthotopic liver transplant population. Liver Transpl 2006;12:352-5.

43. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillfer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE, Investigators D. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: The DIAD study: A randomized controlled trial. JAMA 2009;301:1547-55.

44. Goraya TY, Jacobsen SJ, Pellikka PA, Miller TD, Khan A, Weston SA, Gersh BJ, Roger VL. Prognostic value of treadmill exercise testing in elderly persons. Ann Intern Med 2000;132:862-70.

45. Blair SN, Kohl HW 3rd, Paffenbarger RS Jr, Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA 1989;262:2395-401.

46. Gulati M, Pandey DK, Arnsdorf MF, Lauderdale DS, Thisted RA, Wicklund RH, Al-Hani AJ, Black HR. Exercise capacity and the
risk of death in women: The St James Women Take Heart Project. Circulation 2003;108:1554-9.
47. Kokkinos P, Myers J, Kokkinos JP, Pittaras A, Narayan P, Manolis A, Karasik P, Greenberg M, Papademetriou V, Singh S. Exercise capacity and mortality in black and white men. Circulation 2008;117:614-22.
48. Mandsager K, Harb S, Cremer P, Phelan D, Nissen SE, Jaber W. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Netw Open 2018;1:e183605.
49. Bradley SM, Soine LA, Caldwell JH, Goldberg SL. Screening stress myocardial perfusion imaging and eligibility for liver transplantation. Am J Cardiol 2010;105:1010-3.
50. Kemmer N, Case J, Chandna S, Neff GW. The role of coronary calcium score in the risk assessment of liver transplant candidates. Transpl Proc 2014;46:230-3.
51. Akincioglu C, Malhotra S. Low yield of routine stress testing in patients awaiting liver transplantation. J Nucl Cardiol 2020;27:266-8.
52. Poulin MF, Chan EY, Doukky R. Coronary computed tomographic angiography in the evaluation of liver transplant candidates. Angiology 2015;66:803-10.
53. Satapathy SK, Vanatta JM, Helmick RA, Flowers A, Kedia SK, Jiang Y, Ali B, Eason J, Nair SP, Ibebuogu UN. Outcome of liver transplant recipients with revascularized coronary artery disease: A comparative analysis with and without cardiovascular risk factors. Transplantation 2017;101:793-803.
54. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, Pierpont G, Santilli S, Rapp J, Hattler B, Shunk K, Jaenicke C, Thottapurathu L, Ellis N, Reda DJ, Henderson WG. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 2004;351:2795-804.
55. Wong EY, Lawrence HP, Wong DT. The effects of prophylactic coronary revascularization or medical management on patient outcomes after noncardiac surgery—A meta-analysis. Can J Anaesth 2007;54:705-17.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.